Patients with recurrent or metastatic disease who will be entering the growing number of clinical trials where a robust assessment of ARID1A protein expression in the tumour could be informative will require a test that is accurate and reproducible with a fast turn‐around time. Here, ARID1A is linked to neoplasm.